In Brief This Week: Sequenom; Geneart, Life Technologies; Thermo Fisher Scientific; Spartan Bioscience; BioTime | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Sequenom this week said that it will begin a validation study of its SensiGene T21 Laboratory-Developed Test in January. The firm has received its first set of clinical samples and will conduct the study at its reference lab, the Sequenom Center for Molecular Medicine.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: a sequencing-based screen of Lyme disease-causing pathogen, the range of animals bitten by Anopheles darling mosquitoes in Peru, and more.

An NC State researcher is exploring the use of CRISPR-Cas3 as an anti-microbial, Gizmodo reports.

The Earth BioGenome Project plans to sequence all life on Earth, according to ScienceInsider.

For those who are concerned about Trump administration actions related to science, a new column in Scientific American has suggestions for ways to fight back.